Telix Pharmaceuticals Limited ADR (TLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | |
| Cash Flows From Operating Activities | ||
| Net Income | 36,980 | 2,051 |
| Depreciation Amortization | 5,290 | 4,480 |
| Accounts receivable | -37,656 | -18,193 |
| Accounts payable and accrued liabilities | 28,964 | 22,393 |
| Other Working Capital | -42,400 | -22,261 |
| Other Operating Activity | 37,208 | 27,399 |
| Operating Cash Flow | $28,386 | $15,869 |
| Cash Flows From Investing Activities | ||
| Change In Deposits | -34,297 | -8,740 |
| PPE Investments | -9,448 | -6,431 |
| Net Acquisitions | -20,378 | N/A |
| Purchase Sale Intangibles | -13,003 | -741 |
| Other Investing Activity | -25,051 | -1,764 |
| Investing Cash Flow | $-89,174 | $-16,935 |
| Cash Flows From Financing Activities | ||
| Debt Issued | 432,722 | 3,824 |
| Debt Repayment | -736 | 0 |
| Common Stock Issued | 659 | 4,420 |
| Other Financing Activity | -11,148 | -1,476 |
| Financing Cash Flow | $421,498 | $6,768 |
| Exchange Rate Effect | 26,606 | -1,112 |
| Beginning Cash Position | 81,300 | 77,289 |
| End Cash Position | 468,615 | 81,879 |
| Net Cash Flow | $387,316 | $4,590 |
| Free Cash Flow | ||
| Operating Cash Flow | 28,386 | 15,869 |
| Capital Expenditure | -9,448 | -6,431 |
| Free Cash Flow | 18,938 | 9,438 |